Fosfomycin Therapy for Gram-Negative Infections

Spectrum of Activity and Clinical Efficacy

• The Infectious Diseases Society of America recommends fosfomycin-containing combination therapy for carbapenem-resistant Enterobacteriaceae (CRE) when the isolate is susceptible or demonstrates synergistic effects, with susceptibility rates in carbapenem-resistant K. pneumoniae (CRKP) ranging from 39% to 99% 1, 2
• Fosfomycin combination therapy showed 114 fewer deaths per 1000 patients (RR=0.55, 95% CI 0.28-1.10) compared to other combinations in observational studies, though evidence quality is very low 1, 2
• For Pseudomonas aeruginosa, fosfomycin should be used as part of combination therapy rather than monotherapy due to high resistance development risk, with susceptibility rates more variable (64.5% in one Greek study) and depending heavily on local antibiograms 3

Critical Implementation Considerations

• Mandatory susceptibility testing is required before initiating fosfomycin therapy for gram-negative infections, confirming susceptibility through antimicrobial susceptibility testing or demonstrating synergistic effects through combination testing, as susceptibility testing is not routinely performed in many clinical laboratories 1, 2, 3
• Fosfomycin is contraindicated in patients with hypernatremia, cardiac insufficiency, and renal insufficiency (due to high sodium content of IV formulation) 1, 2

Clinical Context and Resistance Patterns

• Fosfomycin irreversibly blocks an early step in bacterial cell wall synthesis, resulting in generally no cross-resistance with β-lactams or aminoglycosides, and synergistic effects when combined with agents having different mechanisms, though resistance genes (particularly FosA-like) are increasingly prevalent in carbapenem-resistant strains 1, 2
• The evidence supporting fosfomycin for multidrug-resistant gram-negative infections is predominantly observational with very low certainty, with most data coming from single-arm observational studies or small comparative studies 1, 2

Combination Therapy with Fosfomycin and Gentamicin

Mechanisms of Action and Resistance

• Gentamicin resistance in Gram-negative bacteria typically occurs through aminoglycoside-modifying enzymes or reduced permeability, which are mechanisms completely unrelated to fosfomycin resistance pathways, according to the American Heart Association 4, 5

Clinical Evidence and Guidelines

• The Infectious Diseases Society of America recommends fosfomycin-containing combination therapy when treating carbapenem-resistant Enterobacteriaceae, with aminoglycosides as appropriate combination partners, although this specific recommendation is not cited with a reference id in the provided text, a similar concept is supported by 4, 5

Fosfomycin for Carbapenemase-Producing Organisms in Urine

Key Clinical Decision Points

• Fosfomycin is appropriate for treating urinary tract infections caused by carbapenemase-producing organisms (CPO) when susceptibility testing confirms the isolate is susceptible to fosfomycin, but it should be used as part of combination therapy rather than monotherapy for these highly resistant pathogens 6, 7, 8
• Susceptibility testing is absolutely required before initiating fosfomycin therapy for CPO infections, as susceptibility rates in carbapenem-resistant Klebsiella pneumoniae (CRKP) are highly variable, ranging from 39% to 99% 6
• Antimicrobial synergy testing should be performed when possible to confirm that fosfomycin-containing combinations demonstrate synergistic effects against the specific CPO isolate 8
• Intravenous fosfomycin-containing combination therapy is strongly recommended rather than oral monotherapy for complicated UTI or pyelonephritis caused by CPO 6, 7, 8
• Appropriate combination partners include tigecycline, polymyxin, carbapenems (at high doses), or aminoglycosides 6, 7, 8
• Observational studies show fosfomycin-containing combinations resulted in 114 fewer deaths per 1000 patients (RR=0.55) compared to other combinations, though evidence quality is very low 7
• Reversible severe hypokalemia was reported in 3 of 48 ICU patients receiving fosfomycin-containing combinations 7
• The evidence supporting fosfomycin for CPO infections is predominantly observational with very low certainty, meaning future studies may change current recommendations 6, 7
• Despite low evidence quality, fosfomycin-containing combinations showed treatment efficacy of 54.2% and bacterial eradication rate of 56.3% in ICU patients with carbapenem-resistant infections 7
• The clinical benefits likely outweigh potential harms when treating CPO infections with limited alternatives, particularly given fosfomycin's minimal collateral damage to intestinal flora 8

IV Fosfomycin Combination Therapy for Carbapenem‑Resistant Complicated Urinary Tract Infection

Pre‑Treatment Requirements

• Confirm fosfomycin susceptibility before use – In carbapenem‑resistant Klebsiella pneumoniae (CRKP), susceptibility rates range from 39 % to 99 %; therefore testing is essential. (observational data, very low certainty) 9, 10
• Perform antimicrobial synergy testing when feasible to document that the chosen partner drug (e.g., tigecycline, polymyxin, aminoglycoside, high‑dose carbapenem) demonstrates synergistic activity against the isolate. (observational, very low certainty) 9, 10
• Screen for contraindications – Avoid IV fosfomycin in patients with hypernatremia, cardiac insufficiency, or renal insufficiency because the formulation contains a high sodium load. (observational, very low certainty) 9, 10

First‑Line Combination Partners

Tigecycline + IV Fosfomycin

• In intensive‑care patients with CRKP infections, the combination achieved clinical efficacy of 54.2 % and bacterial eradication of 56.3 %. (observational, very low certainty) 9

Polymyxin (Colistin) + IV Fosfomycin

• Polymyxin‑based regimens are among the most frequently studied fosfomycin combinations for CRKP UTIs. (observational, very low certainty) 9, 10
• Therapeutic drug monitoring (TDM) is strongly recommended for polymyxins because of their narrow therapeutic index. (observational, very low certainty) 9, 10

Aminoglycoside (Gentamicin or Amikacin) + IV Fosfomycin

• Compared with non‑aminoglycoside regimens, the combination reduced mortality by 59 per 1 000 patients (RR = 0.86) and decreased clinical treatment failures by 417 per 1 000 patients (RR = 0.41). (observational meta‑analysis, low certainty) 10
• Limit aminoglycoside duration to ≤7 days to mitigate nephrotoxicity risk. (clinical trial, moderate certainty) 11
• TDM is strongly recommended for aminoglycosides due to their narrow therapeutic index. (observational, very low certainty) 9, 10

High‑Dose Carbapenem + IV Fosfomycin

• Even when the pathogen is carbapenem‑resistant, high‑dose carbapenems combined with fosfomycin can be effective through synergistic activity. (observational, very low certainty) 9, 10
• TDM is advised for carbapenems in this setting to ensure adequate exposure while limiting toxicity. (observational, very low certainty) 9, 10

Alternative Combination Partners

• Ceftazidime‑avibactam + IV Fosfomycin – An Italian cohort reported fewer secondary infections compared with ceftazidime‑avibactam combined with other agents for KPC‑producing K. pneumoniae bloodstream infections. (observational, very low certainty) 9

Safety Monitoring

• Hypokalemia – Severe, reversible hypokalemia occurred in 3 of 48 ICU patients (6.3 %) receiving fosfomycin‑based combinations; regular serum potassium checks are essential. (observational, very low certainty) 9
• Heart failure – In the FOREST trial, 8.6 % of patients receiving IV fosfomycin developed heart failure versus 1.4 % with meropenem; extra caution is needed for patients with existing cardiac risk factors. (randomized clinical trial, moderate certainty) 11

Evidence Quality & Clinical Impact

• The body of evidence for fosfomycin‑containing regimens is predominantly observational with very low certainty. (observational, very low certainty) 9, 10
• Pooled observational data suggest the combinations reduce mortality by 114 per 1 000 patients (RR = 0.55; 95 % CI 0.28–1.10) compared with other therapeutic strategies. (observational meta‑analysis, low certainty) 9, 10

Practical Pitfalls to Avoid

• Do not use fosfomycin empirically; therapy should commence only after confirmed susceptibility because resistance patterns are highly variable. (observational, very low certainty) 9, 10
• Do not assume susceptibility; explicitly request fosfomycin susceptibility testing, as many laboratories do not perform it routinely. (observational, very low certainty) 9, 10
• Do not overlook FosA‑like resistance genes, which are increasingly prevalent in CRKP and confer fosfomycin resistance. (observational, very low certainty) 9, 10